Concomitant i.v. and oral clodronate in the relief of bone pain - a double-blind placebo-controlled study in patients with prostate cancer
1997

Clodronate for Bone Pain Relief in Prostate Cancer

Sample size: 57 publication Evidence: moderate

Author Information

Author(s): T Kylmala, T Taube, TLJ Tammela, L Risteli, J Risteli, I Elomaa

Primary Institution: Tampere University Hospital, University of Helsinki, University of Oulu

Hypothesis

Does combined intravenous and oral administration of clodronate provide better pain relief than oral administration alone in patients with prostate cancer?

Conclusion

The study found that clodronate treatment provided only a modest improvement in pain relief compared to placebo.

Supporting Evidence

  • Pain relief was only about 10% better in the clodronate group than in the placebo group.
  • Performance status was better in the clodronate group at various time points.
  • Statistical significance was observed in performance status at admission and at 1 and 12 months.

Takeaway

Doctors wanted to see if giving clodronate through an IV and by mouth would help men with prostate cancer feel less pain, but it only helped a little bit more than not taking it at all.

Methodology

The study was a double-blind, placebo-controlled trial involving 57 patients with advanced prostate cancer who were treated with clodronate or placebo.

Potential Biases

Potential bias due to the subjective nature of pain assessment.

Limitations

The study had a small sample size and the pain relief was only modest.

Participant Demographics

Patients were men with advanced prostate cancer, with a mean age of 72 years.

Statistical Information

P-Value

p=0.055

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication